CBD


ADVERTORIAL


A bRAND NEW CbD EXPERIENCE!


CbD is a cannabinoid that has an impact on the endocannabinoid system, producing a very wide range of effects. CbD is the nonpsychoactive component in cannabis and is largely known for its health and wellness properties.


Many people associate cannabis with ‘highs’, but the highs are actually created by tetrahydrocannabinol (THC), the illegal chemical within cannabis, which is responsible for loss of control, hallucinations and psychosis. The Green Monkey CbD range has had the THC extracted out of it during the supercritical C02 infusion process.


That means that Green Monkey CbD products can be used without any adverse side effects or ‘highs’.


Green Monkey CbD also offers the UK’s first CbD carbonated drink. CbD has a proven track record of reducing anxiety, and so our Green Monkey CbD carbonated drink is being seen as the perfect drinking partner, helping people to feel


sociable without any of the negative effects of alcohol.


AVPharma works directly with specialist manufacturers in the UK and EU to exclusively distribute the pharmaceutical products to reputable partners throughout the world.


Available exclusively through Phoenix, the range covers all delivery mechanisms to suit patients’ tastes and budgets including balms, capsules and the more traditional oils.


We make no medical claims with our products, and so we advise that potential users research their particular ailment and the impact CbD may have on it diligently before they make a purchase.


To make enquiries about the Green Monkey CbD range, visit av-pharma.com. Not only will you be able to view our great range of products but you’ll be able to access our excellent pharmacy training module. www.greenmonkeycbd.co.uk


> effect, while Cb2 receptors are attached to CbD, providing an immunomodulatory and pain suppression effect.


What’s available at the minute?


At the moment there are only two cannabis-based pharmaceutical drugs, which are manufactured in the UK and which are licensed for prescription, but only for very specific uses.


Sativex has been used in the UK since 2010 to treat spasticity in multiple sclerosis and uses THC and CbD in a 50:50 ratio.


A new CbD-drug only rug, Epidiolex, meanwhile, was approved in June in the USA to treat rare childhood epilepsies and it is expected that similar approval will be granted soon in the UK.


DIFFICULTIES/CHALLENGES PRESENTED BY CANNABIS- BASED PRODUCTS Simply put, the main problem regarding these products is that, while there is a lot of research being carried out in the treatment of many different conditions, most of it is in the early stages and so most of the evaluation and evidence is currently, at best, theoretical.


Pain management is an excellent example of the current confusion. At present, for example, there are no cannabis-based products routinely commissioned for use, and both the Faculty of Pain Medicine and the british Pain Society support the view that further research is required to evaluate the safety, efficacy and harms of cannabis-based preparations in pain management. Specialists are also awaiting NICE guidelines to support the prescribing of cannabis- based products. This is expected by October 2019.


Healthcare professionals also recommend that patients should not


be referred to secondary care for cannabis-based products for pain due to the lack of good evidence associated with their use and the risk of adverse effect. This includes neuropathic, non-malignant and cancer pain.


SO, WHERE DOES THAT LEAVE THE PHARMACIST? After all, since cannabinoid treatments are now available in the UK in everything from skin creams to beers, it is the pharmacist that many patients will look to for advice and information.


There is no doubt that, in the current climate of few evidence-based outcomes and evaluation that is simply theoretical, the pharmacist is still the best source of information with regard to these products.


While CbD is available from many outlets, while uncertainty exists with regard to contraindications etc, the pharmacist is best placed to make suggestions to patients based on pharmaceutical and clinical evidence.


With media interest in CbD high at the moment, many patients are going to the pharmacy looking for ‘wonder cures’ for pain etc based on newspaper and magazine articles.


While pharmacists can certainly suggest that patients try such products in a rational and controlled manner, the interventions and consultations can provide the pharmacist with the opportunity to both advise on possible contraindications and also to have a general discussion on lifestyle and well-being advice that may help the patient with their particular healthcare issue.


The direction of travel for pharmacies has to be into spearheading an informed and well-controlled, evidence-based treatment approach in a clinical setting.


There is no doubt that, in the current climate of few evidence-based outcomes and evaluation that is simply theoretical, the pharmacist is still the best source of information with regard to these products


PHARMACY IN FOCUS - 25


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48